Naval Daver, MD
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Naval Daver, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:00 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03850574 · Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid LeukemiaAptose Biosciences Inc. · recruiting · Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML · principal investigator
- N/ANCT03259230 · Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic LymphohistiocytosisSwedish Orphan Biovitrum · completed · Hemophagocytic Lymphohistiocytosis · principal investigator
- Ph1/Ph2NCT02829840 · Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · withdrawn · Leukemia, FLT3-Mutated Acute Myeloid Leukemia, FLT3-Mutated High-Risk Myelodysplastic Syndrome · principal investigator
- Ph1/Ph2NCT02530476 · Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid LeukemiaM.D. Anderson Cancer Center · completed · Leukemia, Acute Myeloid Leukemia · principal investigator
- Ph2NCT02420873 · An Open-label Phase II Study of Lorvotuzumab MertansineM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT02385110 · Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic LymphohistiocytosisM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1NCT02225574 · An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph1/Ph2NCT01893320 · Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT01787487 · Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative NeoplasmM.D. Anderson Cancer Center · completed · Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase · principal investigator
- Ph2NCT00038610 · Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic LeukemiaM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SPORE University of Texas M. D. Anderson Cancer Center-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Elizabeth J Shpall · fiscal years 2003 to 2023Named on NCT02530476
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in acute myeloid leukemia.